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Scope and purpose  
Background  
Axial spondyloarthritis (axSpA) is a chronic inflammatory condition predominantly involving 
the spine and sacroiliac joints (SIJ), with or without extra-spinal manifestations including 
peripheral arthritis, enthesitis, iritis, psoriasis and inflammatory bowel disease.  Individuals 
with axSpA experience significant pain, stiffness and lack of function which translates into 
important health-economic costs and increased mortality.   
Axial SpA can be classified into two subgroups: radiographic axSpA, commonly referred to 
as ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA). The primary 
difference between these two subgroups is the presence or absence of defined structural 
changes in the SIJ as detected on plain radiography.  A diagnosis of AS can be made 
according to the modified New York criteria when radiographs show at least grade 2 
sacroiliitis bilaterally or grade 3 unilaterally, in the presence of appropriate clinical 
symptoms[1]. In contrast, SIJ radiographs may be completely normal in nr-axSpA. The 
radiographic changes of AS may take 8-10 years to manifest, with a progression rate from 
nr-axSpA to AS of approximately 12% every 2 years [2], although some patients with nr-
axSpA never develop AS.  Disease progression is predicted most strongly by the presence 
of the HLA-B27 haplotype and severe sacroiliitis on MRI at clinical presentation [3].  
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The aims of treatment in axSpA are to reduce inflammation, relieve pain and stiffness, 
preserve spinal mobility and prevent the development of syndesmophytes.  Although there is 
limited evidence that non-steroidal anti-inflammatory drugs (NSAIDs) may slow the 
development of radiographic change[4], standard treatment is essentially symptomatic.  In 
contrast to peripheral arthritis, disease modifying anti-rheumatic drugs (DMARDs) have no 
effect on symptoms or progression of axial disease[5,6]. 
 
Need for updated guideline  
Several major developments have occurred since the publication of the previous BSR 
guidelines[7], necessitating a revision.  Firstly, the 2005 guidelines applied only to the subset 
of patients with established AS.  However, the concept of axSpA has fundamentally changed 
in the past decade, primarily led by improvements in imaging techniques.  A growing amount 
of data shows that patients with nr-axSpA suffer a similar disease burden[8] and may derive 
as much benefit from treatment as patients with established AS.  To ensure best care, 
treatment guidelines should apply to the whole spectrum of axSpA.  Additionally, according 
to current National Institute for Health and Care Excellence (NICE) guidance[9], AS patients 
may  only switch to a second anti-TNF drug within the first 12 weeks of treatment, and then 
only if they suffer an adverse event.  Recent published evidence now supports the 
sequential use of two or more anti-TNF drugs in patients who have failed to respond due to 
inefficacy or toxicity[10,11], and continuing to deny patients effective treatment is untenable.  
Finally, the therapeutic arsenal has expanded over the past decade to include not just anti-
TNF drugs but other biologic agents and biosimilar drugs, and these have been included in 
the most recent literature search.   
 
Objectives of the guideline  
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These guidelines provide evidence-based guidance for UK clinicians prescribing biologics for 
adult patients with axSpA.  This includes the criteria for starting treatment, the choice of drug 
and assessing response to treatment.  
 Peripheral spondyloarthritis and juvenile SpA are outside the scope of these guidelines, and 
readers are referred to the BSR 2012 guidelines for the management of psoriatic 
arthritis[12].  While a systematic approach was adopted to assess the efficacy of biologic 
drugs in axSpA, this did not include a health economic evaluation.  
Most safety concerns with anti-TNF therapies are common to their use in all inflammatory 
conditions, and to avoid overlap between BSR guidelines it has been decided that the 
generic safety aspects will be addressed by a separate BSR guideline on the safety of 
biologic therapies in inflammatory arthropathies[13]  (currently under revision).  These 
guidelines therefore consider only those safety aspects of specific relevance to axSpA. 
 
Target audience  
These guidelines are intended primarily for Rheumatologists and other clinicians prescribing 
biologic drugs  for the treatment of people with axSpA.  However, they will also be of interest 
to specialist nurses, allied health professionals and general practitioners (GPs) involved in 
monitoring treatment and assessing response. 
 
Stakeholder involvement  
These guidelines have been written by a working party established by the BSR whose 
membership includes rheumatologists, allied health professionals, a GP, a patient 
representative and a representative from the National Ankylosing Spondylitis Society 
(NASS).  Full details including conflicts of interest are listed at the end of this paper.  The 
guidelines were presented for comment at the BSR Annual Meeting in 2015. 
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Rigour of Development  
Scope of the literature search and strategy employed L2 
The evidence for these guidelines is based on a systematic literature search of Medline, 
EMBASE and the Cochrane library up to 30th June 2014.  The working group defined the 
terms of the search using a Patient Intervention Comparison Outcome (PICO) format, where 
patients were individuals with AS or nr-axSpA, the intervention was biologics, the 
comparator was placebo and the outcomes were measures of disease activity, function, 
spinal mobility and radiological severity.  Structured key questions were developed by the 
group as a whole (individual questions are listed in the appendix) with search terms as 
follows: 
 
(SPONDYLITIS, ANKYLOSING/OR AS OR spondyloarthr* OR spondylarthr* OR SpA OR 
sacroiliitis) AND (infliximab OR remicade OR etanercept OR enbrel OR adalimumab OR 
humira OR certolizumab OR cimzia OR abatacept OR orencia OR golimumab OR simponi 
OR tocilizumab OR roactemra OR ustekinumab OR stelara OR efalizumab OR raptiva OR 
anakinra OR kineret OR alefacept OR amevive OR rituximab OR mabthera OR anti-TNF or 
“TNF inhibitor” OR biologic) 
 
The search was limited to articles in English.  Outcomes of interest were efficacy in AS 
(including total ankylosis) and nr-axSpA,, comparing biologics, switching and withdrawing 
treatment, intermittent and changed dosing, predictors of response, outcome measures 
including radiographic outcomes, effect on extra-articular features, work productivity and 
absenteeism, utilisation of healthcare (all categorised as ‘efficacy’ in figure 1),and side 
effects, vaccine safety, reproductive safety and safety in patients with viral hepatitis or HIV 
(grouped as ‘safety’ in figure 1).  The search terms and outcomes of interest were agreed by 
the working group in advance of the literature search. 
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For efficacy outcomes, only high-quality meta-analyses, systematic reviews or RCTs were 
considered, unless no other data was available for a particular outcome in which case 
observational studies with control arms were reviewed.  For safety outcomes, controlled 
observational studies were accepted.  Conference abstracts less than two years old were 
accepted unless the same data had been subsequently published. 
 
Titles and abstracts were screened, and relevant full papers were each graded by two 
members according to the system used by the Scottish Intercollegiate Guidelines Network 
(SIGN)[14] (table 1).  A summary of the results of the literature search is shown in Fig. 1. 
 
Based on the literature review, the working party developed recommendations for treatment.  
All members then anonymously stated their level of agreement with each statement on a 0-
10 scale where 10 is total agreement.  The resulting consensus scores are given for each 
recommendation below. 
 
 
Statement of extent of NICE, RCP, SIGN guidelines  
Since the last BSR guidelines, NICE has published guidelines for biologics in AS (TA 143 
(2008), currently being updated), and the Assessment of SpondyloArthritis international 
Society( ASAS) and the European League Against Rheumatism (EULAR) produced updated 
guidelines in 2010 which included the treatment of non-radiographic disease[15].  There 
have been no SIGN guidelines for the treatment of AS. 
 
  
Statement of when guidelines will be updated  
The literature review will be updated in 2017 to inform a revision of the guidelines in three 
years’ time. 
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The guideline  
An algorithm for the use of biologics in axSpA, summarising the recommendations below, is 
shown in figure 2. 
 
Eligibility criteria  
These guidelines apply to adult patients with axSpA, including those meeting the modified 
New York criteria[1] and those with total ankylosis.  The diagnosis of axSpA is beyond the 
scope of these guidelines.  However, it should be emphasised that the ASAS classification 
criteria for axSpA[16] are not intended to be used as diagnostic criteria.  While the European 
Medicines Agency (EMA) has approved the use of several anti-TNF drugs in patients with 
nr-axSpA, the US Food and Drug Administration (FDA) has not allowed the treatment of 
patients who do not fulfil the modified New York criteria, citing several concerns related to 
inappropriate diagnosis and treatment[17].    Clinicians should not use biologic drugs in 
patients who have no objective signs of inflammation, and/or whose symptoms or raised C-
reactive protein (CRP) might be due to conditions other than axSpA, even if they appear to 
fulfil the ASAS classification criteria.  As always, guidelines are not a substitute for clinical 
judgement.  Discussion with an axSpA specialist should be considered before starting 
treatment in a patient with nr-axSpA and no sacroiliac joint bone marrow oedema on MRI. 
 
Assessment of disease and response to treatment  
Anti-TNF drugs in AS  
Eighteen eligible RCTs were identified which evaluated the efficacy of the five currently 
available TNF inhibitors (adalimumab, certolizumab, etanercept, golimumab and infliximab) 
in patients with AS. The main characteristics and outcomes of these trials are shown in 
Table 2. These trials all had a placebo control arm apart from one study with sulfasalazine 
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as control[18] and one which compared two doses of etanercept[19]. While the trials used a 
variety of definitions of “active” disease, 10 of the 16 placebo controlled studies used 
BASDAI (and spinal pain VAS in most) ≥4 as inclusion criteria (see Table 2). This definition 
of active disease was used in the seminal phase III AS studies for all of the TNF inhibitors, 
apart from etanercept[20]. 
Similarly, the studies used a variety of primary efficacy end-points and time points. The 
inclusion criteria for eight studies also required the presence of active disease despite 
treatment with standard therapy (NSAIDs), due to either inadequate response or intolerance.  
Ten of the 16 placebo-controlled RCTs, including all the seminal phase III studies, used the 
ASAS20 response rates as primary efficacy outcome, with the time scale varying between 
12-24 weeks. The ASAS20 response rate defines the proportion of patients achieving an 
improvement of ≥20% and ≥1 unit compared with baseline in ≥3 of the following 4 domains: 
patient’s global assessment of disease activity, patient’s assessment of pain, function 
(represented by the BASFI) and inflammation (represented by the mean of BASDAI 
questions 5 and 6 relating to morning stiffness); with no deterioration (worsening of ≥20% or 
1 unit) in the remaining domain[21]. All of the placebo-controlled trials achieved the primary 
efficacy end-point, apart from one early study where the primary end-point (BASDAI) was 
assessed 8 weeks after the last infusion of infliximab[22]. The RCTs also demonstrated 
efficacy of the TNF inhibitors for a variety of other secondary clinical and patient reported 
outcomes. A meta-analysis of TNF inhibitors (no certolizumab studies were included) 
reported that patients treated with anti-TNF agents were more likely to display an ASAS20 
response after 12 to 14 weeks (RR 2.21; 95 % CI 1.91; 2.56) and 24 weeks (RR 2.68; 95 % 
CI 2.06; 3.48) compared with controls, which was also true for several other efficacy 
outcomes[23]. An earlier systematic literature review estimated that treatment effect sizes for 
anti-TNF agents versus placebo varied between 0.34 (95%CI:0.08-0.6) and 1.5 
(95%CI:0.45-2.5) for BASDAI, with numbers needed to treat of 2.3-2.7 for ASAS20 
responses[24].  
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While several early RCTs excluded patients with advanced or complete spinal fusion, one 
study specifically evaluated the efficacy of etanercept in patients with advanced radiographic 
spinal disease[25]. Improvement in BASDAI at 12 weeks, the primary end point, was 
significantly greater in the etanercept group compared with placebo. ASAS20 and ASAS40 
responses were similar to those seen in trials for patients without advanced spinal disease. 
The presence of vertebral or sacroiliac joint fusion should not therefore preclude the use of 
anti-TNF therapy. 
 
Biosimilar drugs in AS  
The PLANETAS study was the only RCT of an anti-TNF biosimilar in AS [26]. Patients with 
AS were randomised to receive either CT-P13 (biosimilar of infliximab; Inflectra or Remsima) 
or innovator Remicade (infliximab). The regulators require biosimilars to demonstrate proof 
of similarity of effect, but not de novo efficacy. The comparable efficacy of CT-P13 with 
infliximab had already been demonstrated for RA in the PLANETRA study [27], and is 
therefore not required for AS due to indication extrapolation (meaning the biosimilar license 
applies to all the same indications as the innovator biologic, without requiring separate RCTs 
for each indication). The primary outcome in the PLANETAS study was pharmacokinetic 
equivalence at steady state, with no statistically significant differences in the secondary 
clinical outcomes at week 14 or 30 (week 14 ASAS20 62.6% for CT-P13 and 70.5% for 
Remicade). An indirect meta-analysis reported similar efficacy of the infliximab biosimilar 
compared to the other TNF inhibitors[28]. 
The BSR in its position statement on biosimilars[29] recommends that all patients starting on 
or switching to a biosimilar drug should be registered with the BSR Biologic Register 
(BSRBR), and that the decision to prescribe a biosimilar should be made primarily on clinical 
and not cost grounds.  In particular, there is no evidence from clinical trials in axSpA to 
support switching patients who have responded to an innovator biologic to an anti-TNF 
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biosimilar, and such decisions should be made for clinical reasons and on a case-by-case 
basis.  
 
Other biologic drugs in AS  
No non-anti TNF biologic can currently be recommended for the treatment of AS.  When the 
literature review period ended in June 2014, either efficacy had not been established in a 
controlled trial, or potential agents were not licensed for this indication. Several new biologic 
and small molecule inhibitor agents are currently undergoing evaluation and may become 
available in the near future. A single proof-of-concept study of secukinumab (anti-IL17A 
monoclonal antibody) in AS was identified, which suggested a 99.8% probability that 
secukinumab is superior to placebo based on the ASAS20 at 6 weeks[30]. Further studies 
have been published subsequently[31].  Although secukinumab is not currently 
recommended for AS, it has recently been licensed for this indication and we anticipate 
separate guidance on its use will be issued in due course.  A single phase II study of 
apremilast, a small molecule oral phosphodiesterase 4 inhibitor, in AS failed to reach its 
primary outcome (change in BASDAI at week 12), although the clinical results and 
biomarkers suggest it may be effective for AS[32]. Apremilast is not recommended for AS. 
 
Anti-TNF drugs in nr-axSpA  
Six eligible studies examined the efficacy of anti-TNF therapy in patients with nr-axSpA [33–
38] (table 2), although at present only etanercept, adalimumab and certolizumab are 
licensed for this indication.  The trial designs were heterogeneous.  Of the studies only two 
specifically excluded patients with AS. In the others the proportion of patients with 
radiographic sacroiliitis ranged from 12% to 57.5%, though Landewe et al found no 
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significant difference in treatment effect with certolizumab between the AS and nr-axSpA 
groups. 
The two studies excluding AS patients were also the only studies in which active MRI 
inflammation was not a prerequisite.  In Haibel et al, eligibility required either inflammation 
on MRI or HLA-B27 positivity.  The majority (55%) of the intervention group had bone 
marrow oedema in the spine or sacroiliac joints on MRI, but neither inflammation in these 
areas nor HLA-B27 were predictive of a major clinical response.  In Sieper et al’s ABILITY-1 
study only half of those in the intervention group had ever had SIJ inflammation on MRI and 
again this did not affect the proportion meeting the primary outcome measure.  The 
remainder fulfilled the ASAS criteria through the clinical arm.  In the other studies, all 
patients had evidence of inflammation on MRI scan and most had an elevated CRP at 
baseline in addition.  Based on this evidence the use of anti-TNF therapy in nr-axSpA 
patients can only be recommended in the presence of objective signs of inflammation, 
namely positive sacroiliac joint MRI and/or raised CRP.  There is no current high-
quality evidence for the use of any other biologic drugs in nr-axSpA. 
 
Radiological and other outcomes with anti-TNF drugs  
Short term MRI data support the efficacy of TNF inhibitors in the treatment of spinal and 
sacroiliac joint inflammatory lesions in axSpA.  Evidence for anti-TNF therapy on 
radiographic disease progression (new bone formation and ankylosis) is currently limited.  
Large, controlled, longer term clinical trials are needed to clarify whether these drugs may be 
disease modifiers.   
Data on work participation, presenteeism, absenteeism and productivity relating to the 
effects of TNF inhibition in AS are limited, mainly to extensions of RCTs. Systematic reviews 
of the literature show a trend towards benefit from the use of anti-TNF drugs in AS[39] 
although the data are predominantly from patients with longstanding disease[40,41]. Health-
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related quality of life (HRQOL) measures improve with all available anti-TNF 
therapies[42,43], and studies have shown a reduction in hospital admissions[44].  There are 
insufficient data to suggest differences in HRQOL outcomes between the currently available 
anti-TNF therapies. 
 
Eligibility for treatment  
Before considering anti-TNF therapy, patients should have tried a minimum of two non-
steroidal anti-inflammatory drugs (NSAIDs) at maximal tolerated dose (unless contra-
indicated). Two weeks is sufficient time to see a response, with no further benefit over longer 
periods of treatment[45]. 
Current NICE guidelines require patients to have active spinal disease on two separate 
occasions 12 weeks apart, with the aim of avoiding the overtreatment of patients with a 
short-lived flare of disease.  While patients with axSpA do experience variability in symptom 
intensity, this fluctuation is less pronounced than the sometimes dramatic flares seen in 
conditions such as rheumatoid arthritis (RA).  Generalised flares in AS last for an average of 
2-3 weeks[46], and a Canadian study assessing 141 patients with AS starting anti-TNF 
therapy found only 1 patient in whom a second BASDAI (calculated after at least 8 weeks) 
fell below 4[47]. An interval of 4 weeks between scores is therefore sufficient and should not 
delay treatment unduly.  However, prescribers should be confident that worsening 
symptoms, radiological changes and raised inflammatory markers are due to axSpA and not 
to other pathology such as malignancy or infection.  
 
Recommendations for treatment eligibility  
(i) Anti-TNF therapy is effective at reducing disease activity and spinal pain in 
axSpA.(Level of evidence (LOE) 1+; strength of recommendation A; consensus 
score 9.6) 
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(ii) Currently there is insufficient evidence to recommend the use of other biologic 
agents in axSpA (LOE 1+; strength of recommendation B; consensus score 9.3) 
 
(iii) Patients should be considered for anti-TNF therapy if they have active axSpA 
(LOE 1+; strength of recommendation B; consensus score 9.6). 
 
(iv) Active disease is defined by a BASDAI and spinal pain VAS ≥ 4 despite standard 
therapy (LOE 1+; strength of recommendation B; consensus score 8.5).  
 
(v) BASDAI should be measured on two occasions at least 4 weeks apart (LOE 2+; 
strength of recommendation C; consensus score 7.2). 
 
(vi) Patients with active disease who do not meet modified New York criteria for AS 
should also have had a positive MRI and/or raised CRP (LOE 1+; strength of 
recommendation B; consensus score 9.3). 
 
Choice of drug  
Rationale  
In the absence of head-to-head comparisons, systematic reviews[48–50] have shown no 
statistical difference in efficacy between infliximab, golimumab, etanercept, or adalimumab in 
the treatment of AS (certolizumab data were not included in these comparative reviews).  
There are insufficient data to comment on relative efficacy in nr-axSpA.  
Data on the use of anti-TNF drugs to treat the extra-articular manifestations of axSpA are 
limited, although a systematic review has shown no statistically significant difference in the 
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rate of uveitis flares in patients with AS treated with infliximab versus etanercept[51].  
Importantly, not all biologics with efficacy in axSpA are licensed for the treatment of 
associated conditions.  In particular, etanercept has no efficacy in the treatment of 
inflammatory bowel disease[52]. Choice of drug should be a mutual decision between 
patient and clinician, taking into account factors such as route and frequency of 
administration, and the presence of comorbidities.  Where relevant, advice might be sought 
from other clinicians managing extra-articular disease. 
Recommendation for choice of drug  
(i) Extra-articular manifestations and patient choice should be considered when 
selecting an anti-TNF agent (LOE 4; strength of recommendation D; Consensus 
score 8.9). 
 
Assessing response and monitoring treatment  
Rationale  
Improvement with anti-TNF drugs is generally seen within the first 6-8 weeks of treatment, 
and the majority of RCTs assessed primary endpoints at 12 weeks.  However, time to 
maximal improvement may be longer than three months[53], and a proportion of patients will 
meet the primary endpoint beyond 12 weeks.  In a trial of etanercept vs sulfasalazine in 
AS[18], 75.9% of patients taking etanercept achieved ASAS20 at week 16 compared to 
70.9% at week 12.  We suggest therefore that a diagnosis of non-response should not be 
made before six months.  
Those patients who have responded to treatment should be reviewed every six months by 
their rheumatology team.  This allows an evaluation of drug efficacy and tolerability to be 
made, outcome measure data to be collected, and specific issues such as pregnancy and 
surgery to be discussed with patients.  Most patients with axSpA will not be taking 
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concomitant non-biologic DMARDs, so the frequency of any blood monitoring should be 
determined by local practice and guidelines, and the manufacturers’ recommendations. 
  
In keeping with international recommendations from the ASAS group, outcome measures 
should be used that capture the range of outcome domains in axSpA, including pain; 
physical function; spinal mobility; patient global assessment; peripheral joints and entheses; 
spinal stiffness; and fatigue.  Depending on the timescale, it may be appropriate to use 
spinal x-ray as an outcome, although in clinical practice, when a decision to continue / 
discontinue treatment is warranted, or in short-term clinical trials, this is unnecessary. 
BASDAI and spinal pain VAS have been used to assess disease activity since the 
publication of the last guidelines, and along with BASFI and patient global assessment form 
the ASAS improvement criteria commonly used as a primary outcome measure in clinical 
trials.  While these are subjective measures, they are validated, well-understood by 
clinicians and patients and at the present time we see no reason to adopt other eligibility 
criteria for AS patients. In a small minority of patients (e.g. with cognitive or communication 
difficulties) it will not be possible to assess disease activity using BASDAI.  In this situation, 
the decision to initiate and continue treatment should be made by the treating physician, 
taking into account the patient’s overall symptoms and preferences.   
As a measure of disease activity the Ankylosing Spondylitis Disease Activity Score (ASDAS) 
is perhaps not as widely used as the BASDAI, although includes several of its individual 
questions.  However, early evidence suggests that it may prove to be a more discriminatory 
tool in the assessment of disease activity[54].  As ASDAS is a composite index of patient 
reported outcomes and objectives measures of the acute-phase reaction, we would suggest 
that inflammatory markers are recorded – preferably CRP.  These measures not only have 
some utility themselves, but can also contribute to the computation of the ASDAS.  Machado 
et al[55] found that inflammation on MRI correlated better with CRP than other measures of 
disease activity, and concluded that the ASDAS, by including both CRP and patient-reported 
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outcomes in its formula, better reflects spinal inflammation than other measures of disease 
activity. 
 
Recommendations for assessment of response  
(i) Initial efficacy response should be assessed following 3 to 6 months of therapy 
and responders should then be reassessed every 6 months (LOE 2+; strength of 
recommendation D; consensus score 8.6). 
 
(ii) Response is defined as reduction of BASDAI and spinal pain VAS by 2 or more 
units from baseline (LOE 1+; strength of recommendation B; consensus score 
8.3). 
 
(iii) If, because of cognitive or communication difficulties, BASDAI cannot be used to 
monitor disease activity, the decision to initiate and continue therapy should be 
based on the treating clinician’s assessment of disease activity (LOE 4; strength 
of recommendation D; consensus score 9). 
 
 
Withdrawal of therapy  
Rationale  
The majority of patients will relapse within one year if treatment is withdrawn from those in 
remission (83% relapse with adalimumab after mean 14.7 weeks in nr-axSpA[56]; 77% 
relapse with etanercept in AS[57]).  There is therefore no role for the routine withdrawal of 
treatment in patients who have achieved remission.  Intermittent or ‘on-demand’ dosing of 
infliximab has been shown to marginally reduce costs, at the expense of poorer clinical 
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outcomes, and cannot be recommended[58,59].  There is no high-quality evidence to 
support the routine use of reduced doses of anti-TNF therapy. 
The decision to withdraw treatment because of secondary non-response should not be made 
after a single raised BASDAI, because symptoms are subject to fluctuation.  As noted above 
flares last 2-3 weeks on average[46] so a minimum interval of a month before reassessing is 
suggested. 
 
Recommendations for withdrawal of therapy  
(i) In the absence of an initial clinical response by 6 months, or failure to maintain 
response at 2 consecutive assessments at least 4 weeks apart, withdrawal of that 
anti-TNF agent should be considered (LOE 4; strength of recommendation D; 
consensus score 9.4). 
 
(ii) There is no evidence to support the withdrawal of anti-TNF therapy in treatment 
responders (LOE 2+; strength of recommendation B; consensus score 9). 
 
Switching drugs  
Rationale  
At present, AS patients in the UK are only allowed access to one anti-TNF drug, unless they 
experience an adverse event within 12 weeks of initiating therapy (NICE TA 143). This 
severely limits the therapeutic options for patients with severe AS, particularly in comparison 
to RA where many more biologic treatment options exist. In effect clinicians and patients are 
under pressure to select the ‘correct’ anti-TNF drug first time, not knowing whether extra-
articular features such as IBD will appear later in the disease course, or whether human anti-
chimeric antibodies (HACAs) will mediate a suboptimal response after several years of 
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treatment.  The current NICE position is also at odds with EULAR[60], ASAS[15] and the 
Scottish Medicines Consortium who have not advised against or placed any restriction on 
sequential anti-TNF therapy in axSpA. 
A health economic analysis is outside the scope of these guidelines, so we cannot comment 
on the cost-effectiveness of switching.  Most data on the clinical effectiveness of switching 
comes from registries or open label studies without control arms. However, the literature   
search did identify two studies of sufficiently high quality to be included.  In the NOR-
DMARD cohort[10], 77 of 514 AS patients treated with an anti-TNF drug switched (30 
because of inefficacy, representing <6% of the total anti-TNF-treated population).  
Composite outcome measures were not available for all patients, but the number of patients 
meeting ASAS40 after 3 months of a second anti-TNF drug was 14/45 (31.1%) versus 
76/202 (37.6%) for those who had not switched.  The only significant difference between 
switchers (after 3 months of drug 2) and non-switchers (after 3 months of drug 1) was in the 
proportion achieving BASDAI 50 (28% vs 49% respectively, p=0.007).  In the Czech national 
register ATTRA[11], the response rates of 163 “switch” patients were compared to 1012 
patients treated with a first anti-TNF drug  At week 12, the mean BASDAI was 2.4 in non-
switchers and 2.6 in switchers (p=0.471).  At two years, drug survival was 86% in non-
switchers, 69% in switchers on subsequent therapy and 28% in switchers on first therapy.  In 
both studies, the numbers of patients who needed to switch because of inefficacy was 
extremely small and there was no difference in outcome between those switching due to 
adverse events or inefficacy. No studies have examined switching in nr-axSpA, but there is 
no reason to assume that outcomes would be significantly different in this group.   
Although patients seem to do best if their first anti-TNF drug is both tolerated and effective, 
there is enough evidence to recommend that patients be allowed to switch to alternative anti-
TNF drugs at any point during treatment, whether for reasons of inefficacy or adverse 
events.   
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Recommendation for switching drugs  
(i) In the event of anti-TNF failure due to inefficacy or adverse event, an alternative anti-
TNF agent should be offered if clinically appropriate (LOE 2+; strength of 
recommendation C; consensus score 9.7). 
 
 
Safety  
Overall  
The safety of anti-TNF therapies in axSpA is comparable to other inflammatory joint 
diseases such as RA.  There is little evidence to suggest that safety issues differ hugely with 
different disease groups, and the 2010 BSR guidelines on the safety of anti-TNF therapies in 
RA are applicable in axSpA[13].  Pooled RCT data from Gottlieb et al for 2000 patients 
receiving etanercept (700 with AS) showed a serious infection risk for AS of 3.01/100 patient 
years compared to 3.75 for RA and 3.01 for the whole group[61]. A similar lack of difference 
according to indication was observed for malignancies, opportunistic infections and mortality. 
 
Reproductive safety  
While studies are limited, there is no evidence that anti-TNF therapy adversely affects 
sperm health in men with axial SpA[62].  For issues surrounding female reproductive safety, 
please see the BSR and BHPR guideline on prescribing drugs in pregnancy and 
breastfeeding Part I: standard and biologic disease modifying anti-rheumatic drugs and 
corticosteroids (in development). 
 
Vaccination safety  
The immune response to vaccination may be impaired in axSpA patients on anti-TNF 
therapies, although the data are conflicting.  Two studies[63,64] found the response to 
BSR axSpA biologics full guideline 
 
20 
 
pandemic influenza vaccination to be unimpaired, one study[65] found response to 
pneumococcal vaccination to be impaired only if concomitant methotrexate was used, and 
one study[66] found response to pandemic flu vaccination was impaired by monoclonal 
antibody anti-TNF therapies. 
 
It is recommended that any ‘one-off’ vaccinations required by the patient, such as those to 
prevent pneumonia, should be given before starting treatment. While receiving treatment, 
appropriate annual vaccinations (such as against influenza) should be given when indicated, 
although the responses may be attenuated.  The shingles (herpes zoster) vaccine 
(Zostavax) contains live attenuated virus and therefore is not recommended for patients 
receiving anti-TNF drugs[67]. 
  
TB  
The risk of TB with anti-TNF therapies in axSpA appears similar to that seen in RA.  The risk 
of TB was 561 per 100,000 patient years in an anti-TNF exposed Korean retrospective 
cohort of 354 AS patients[68] compared to 69.8 per 100,000 patient years in the general 
population, a similar increase in relative risk to that seen for anti-TNF treated patients with 
RA in the BSR biologics register (100 per 100,000 patient years for all anti-TNF therapies 
compared to 12 per 100,000 patient years in the general population)[69]. It appears that the 
risk of TB is increased in anti-TNF treated patients regardless of the indication. 
 
It is therefore recommended that the same screening and prophylaxis for TB carried out prior 
to initiating anti-TNF therapy in any patient with inflammatory arthritis should be carried out 
for patients with axSpA, with appropriate vigilance to detect reactivation of TB on treatment 
should this occur.    
 
 
Uveitis  
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Longer term studies are needed to assess the effect of anti-TNF therapies on the risk of 
uveitis in axSpA. A prospective study in 2008 with only 19 patients[70] suggested that 
monoclonal antibody anti-TNF therapies decreased uveitis flares while etanercept increased 
them. However, a much larger subsequent study using pooled RCT data from 8 trials with 
1,323 subjects[71] comparing the incidence of uveitis in patients on etanercept (8.6/100 
patient years) vs placebo (19.3/100 patient years ) found a beneficial effect for etanercept on 
uveitis. This study did not compare anti-TNF therapies and longer term studies are needed 
to address the risk of uveitis in axSpA patients treated with different anti-TNF therapies. 
 
Applicability and utility  
Barriers to implementation  
There are two important differences between these guidelines and the current UK practice 
determined by NICE, namely the recommendation that treatment be extended to patients 
with nr-axSPA and objective evidence of inflammation, and the recommendation that 
sequential anti-TNF therapy be permitted.  NICE guidance is currently under review, and it 
may be that similar changes are adopted.  However, if this does not occur then it is unlikely 
that clinicians (at least outside Scotland) will be able to implement the BSR 
recommendations in full.   
 
Mechanism for audit of the guideline 
An audit proforma to assess compliance with these recommendations is available on the 
BSR website.  It is suggested that this is applied to consecutive patients with axial SpA 
attending clinic, not just those prescribed anti-TNF drugs, as appropriate access to therapy 
is one standard to be measured. 
BSR axSpA biologics full guideline 
 
22 
 
 
Acknowledgements 
Trish Cornell was a member of the working group until February 2014 when she took up a 
post as Rheumatology Nurse Consultant with Abbvie.  
 
Conflicts of Interest 
All members of the Guideline Working Group made declarations of interest in line with the 
BSR Policy. 
LH has received unit funding from Abbvie, MSD, Pfizer and UCB, was sponsored to attend a 
meeting by MSD, and has received a research grant from Pfizer.  NB has received unit 
funding from Novartis, was sponsored to attend a meeting by Abbvie, and has received 
speaker fees from Pfizer and UCB.  DC was sponsored to attend an international meeting by 
Pfizer and NASS receives ‘hands-off’ educational grants from Pfizer, Abbvie, UCB and MSD.  
GJ has received unit funding from Pfizer and Abbvie, and an honorarium from Abbvie. KM 
has received unit funding from Abbvie and Pfizer, was sponsored to attend a meeting by 
MSD and has had a lecture fee and honoraria from Abbvie and honoraria from Novartis and 
UCB together with educational grants from Abbvie to support the Peninsula Rheumatology 
Conference for GPs.  DMarshall has received honoraria from MSD, Pfizer, Wyeth, UCB, 
Celgene and Abbvie. HM-O has received unit funding from Pfizer, has been sponsored to 
attend a meeting by Pfizer, has received honoraria from Abbvie, Celgene, Janssen, MSD, 
Novartis, Pfizer and UCB and has written a scientific paper in conjunction with Pfizer. 
DMurphy was sponsored to attend a meeting by MSD, has received honoraria from UCB 
and Abbvie and sits on an advisory board for Abbvie. CR was sponsored to attend meetings 
by Abbvie, GSK, MSD, Pfizer and Roche, and received honoraria from UCB.  RS is in 
receipt of research grants from Pfizer and Abbvie, has been sponsored to attend educational 
meetings by Abbvie and has received honoraria from Abbvie, Pfizer, UCB and MSD.  SS has 
BSR axSpA biologics full guideline 
 
23 
 
received unit funding from UCB and Pfizer (research) and Jannsen, MSD and Novartis 
(educational events), has been sponsored to attend meetings by Abbvie, Janssen and MSD, 
has received speaker fees from Abbvie, Amgen and UCB and advisory board fees from 
Abbvie, MSD, Pfizer and UCB.  LvR has received speaker and advisory board fees, and 
sponsorship to attend educational meetings, from Abbvie, MSD, Pfizer and UCB.  KG has 
received unit funding from Abbvie, MSD, Pfizer and UCB, has been sponsored to attend 
meetings by UCB, Abbvie, Pfizer, MSD and has received honoraria from Abbvie, MSD, 
Pfizer and UCB.  The other authors have declared no conflict of interest. 
 
References 
1.  Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for 
ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis 
Rheum. 1984;27(4):361–8.  
2.  Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. 
Rates and predictors of radiographic sacroiliitis progression over 2 years in patients 
with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369–74.  
3.  Bennett AN, McGonagle D, O’Connor P, Hensor EMA, Sivera F, Coates LC, et al. 
Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 
status in early inflammatory back pain predict radiographically evident ankylosing 
spondylitis at eight years. Arthritis Rheum. 2008;58(11):3413–8.  
4.  Wanders A, van der Heijde D, Landewé R, Béhier J-M, Calin A, Olivieri I, et al. 
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with 
ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756–
65.  
5.  Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane database 
Syst Rev. Chichester, UK: John Wiley & Sons, Ltd; 2014;11:CD004800.  
6.  Chen J, Veras MMS, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane 
database Syst Rev. 2013;2:CD004524.  
7.  Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, et al. BSR 
guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. 
Report of a working party of the British Society for Rheumatology. Rheumatology 
2005;44(7):939–47.  
8.  Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, et al. 
The early disease stage in axial spondylarthritis: results from the German 
Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60(3):717–27.  
BSR axSpA biologics full guideline 
 
24 
 
9.  NICE TA 143. Adalimumab, etanercept and infliximab for ankylosing spondylitis. 
[Internet]. National Institute for Health and Care Excellence. 2008. Available from: 
http://www.nice.org.uk/guidance/ta143 
10.  Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Rødevand E, Koldingsnes W, et al. 
Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from 
the NOR-DMARD register. Ann Rheum Dis. 2011;70(1):157–63.  
11.  Pavelka K, , Fojtikova M, Hejduk K. Efficacy of the first and subsequent courses of 
anti-TNF therapy in patients with ankylosing spondylitis – results from the Czech 
National Register ATTRA. Reumatologia. 2012;50(4):294–306.  
12.  Coates LC, Tillett W, Chandler D, Helliwell PS, Korendowych E, Kyle S, et al. The 
2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. 
Rheumatology 2013;52(10):1754–7.  
13.  Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, et al. BSR and 
BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 
2010;49(11):2217–9.  
14.  SIGN 50: a guideline developer’s handbook. Edinburgh: SIGN; 2014.  
15.  Van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, 
Landewé R, et al. 2010 Update of the international ASAS recommendations for the 
use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 
2011;70(6):905–8.  
16.  Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The 
development of Assessment of SpondyloArthritis international Society classification 
criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum 
Dis. 2009;68(6):777–83.  
17.  Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, et al. 
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research 
and treatment network and the Assessment of SpondyloArthritis international Society 
in response to the US Food and Drug Administration’s comments and concerns. 
Arthritis Rheumatol (Hoboken, NJ). 2014;66(10):2649–56.  
18.  Braun J, Van Der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig 
AS, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients 
with ankylosing spondylitis: A randomized, double-blind trial. Arthritis Rheum. 
2011;63(6):1543–51.  
19.  Navarro-Sarabia F, Fernández-Sueiro JL, Torre-Alonso JC, Gratacos J, Queiro R, 
Gonzalez C, et al. High-dose etanercept in ankylosing spondylitis: Results of a 12-
week randomized, double blind, controlled multicentre study (LOADET study). 
Rheumatology 2011;50(10):1828–37.  
20.  Van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, 
Juanola X, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly 
in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65(12):1572–7.  
BSR axSpA biologics full guideline 
 
25 
 
21.  Anderson JJ, Baron G, Van Der Heijde D, Felson DT, Dougados M. Ankylosing 
spondylitis assessment group preliminary definition of short-term improvement in 
ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876–86.  
22.  Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O’Connor P, et al. 
Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical 
and imaging study. Ann Rheum Dis. 2005;64(11):1568–75.  
23.  Machado MADÁ, Barbosa MM, Almeida AM, De Araújo VE, Kakehasi AM, Andrade 
EIG, et al. Treatment of ankylosing spondylitis with TNF blockers: A meta-analysis. 
Rheumatol Int. 2013;33(9):2199–213.  
24.  Baraliakos X, Van den berg R, Braun J, van der Heijde D. Update of the literature 
review on treatment with biologics as a basis for the first update of the ASAS/EULAR 
management recommendations of ankylosing spondylitis. Rheumatology 
2012;51(8):1378–87.  
25.  Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, et al. Efficacy of 
etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing 
spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). 
Ann Rheum Dis. 2011;70(5):799–804.  
26.  Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, 
double-blind, multicentre, parallel-group, prospective study comparing the 
pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients 
with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 
2013;72(10):1605–12.  
27.  Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A 
randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy 
and safety of CT-P13 compared with innovator infliximab when coadministered with 
methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann 
Rheum Dis. 2013;72(10):1613–20.  
28.  Baji P, Péntek M, Szántó S, Géher P, Gulácsi L, Balogh O, et al. Comparative efficacy 
and safety of biosimilar infliximab and other biological treatments in ankylosing 
spondylitis: Systematic literature review and meta-analysis. Eur J Heal Econ. 
2014;15(SUPPL. 1).  
29.  British Society for Rheumatology Position statement on biosimilar medicines 
(February 2015) [Internet]. Available from: 
http://www.rheumatology.org.uk/includes/documents/cm_docs/2015/b/bsr_biosimilars
_position_statement_feb_2015.pdf 
30.  Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, Van der heijde D, et al. Anti-
interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing 
spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 
2013;382:1705–13.  
31.  Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. 
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 
2015;373(26):2534–48.  
BSR axSpA biologics full guideline 
 
26 
 
32.  Pathan E, Abraham S, Van Rossen E, Withrington R, Keat A, Charles PJ, et al. 
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing 
spondylitis. Ann Rheum Dis. 2013;72:1475–80.  
33.  Song I-H, Hermann K, Haibel H, Althoff C, Listing J, Burmester G, et al. Effects of 
etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory 
lesions as detected by whole-body MRI (ESTHER): A 48- week randomised controlled 
trial. Ann Rheum Dis. 2011;70:590–6.  
34.  Landewé R, Braun J, Deodhar a, Dougados M, Maksymowych WP, Mease PJ, et al. 
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis 
including ankylosing spondylitis: 24-week results of a double-blind randomised 
placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73(1):39–47.  
35.  Barkham N, Keen HI, Coates LC, O’Connor P, Hensor E, Fraser AD, et al. Clinical 
and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic 
resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009;60(4):946–54.  
36.  Sieper J, Lenaerts J, Wollenhaupt J, Mazurov V, Myasoutova L, Park S-H, et al. 
Double-blind, placebo-controlled, 28-week trial of efficacy and safety of infliximab plus 
naproxen vs naproxen alone: Results from the infliximab as first line therapy in 
patients with early, active axial spondyloarthritis trial, part i. Arthritis Rheum. 
2012;64:S588–9.  
37.  Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of 
adalimumab in the treatment of axial spondylarthritis without radiographically defined 
sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial 
followed by an open-label extension up to week fifty-two. Arthritis Rheum. 
2008;58(7):1981–91.  
38.  Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown M a., 
et al. Efficacy and safety of adalimumab in patients with non-radiographic axial 
spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann 
Rheum Dis. 2013;72:815–22.  
39.  Van der Burg LR, ter Wee MM, Boonen A. Effect of biological therapy on work 
participation in patients with ankylosing spondylitis: a systematic review. Ann Rheum 
Dis. 2012;71(12):1924–33.  
40.  Barkham N, Coates LC, Keen H, Hensor E, Fraser A, Redmond A, et al. Double-blind 
placebo-controlled trial of etanercept in the prevention of work disability in ankylosing 
spondylitis. Ann Rheum Dis. 2010;69(11):1926–8.  
41.  Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D. Impact of age, 
sex, physical function, health-related quality of life, and treatment with adalimumab on 
work status and work productivity of patients with ankylosing spondylitis. J Rheumatol. 
The Journal of Rheumatology; 2010;37(2):385–92.  
42.  Revicki D, Luo MP, Wordsworth P, Wong RL, Chen N, Davis J, et al. Adalimumab 
Reduces Pain, Fatigue, and Stiffness in Patients with Ankylosing Spondylitis: Results 
from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing 
Spondylitis (ATLAS). J Rheumatol. 2008;35(7):1346–53.  
BSR axSpA biologics full guideline 
 
27 
 
43.  Van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, et 
al. Infliximab improves productivity and reduces workday loss in patients with 
ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis 
Rheum. 2006;55(4):569–74.  
44.  Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Impact of anti-tumour 
necrosis factor alpha treatment on admissions to hospital and days of sick leave in 
patients with ankylosing spondylitis. Ann Rheum Dis. 2004;63(12):1670–2.  
45.  Van der Heijde D, Baraf HSB, Ramos-Remus C, Calin A, Weaver AL, Schiff M, et al. 
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-
week, randomized, controlled study. Arthritis Rheum. 2005;52(4):1205–15.  
46.  Cooksey R, Brophy S, Gravenor MB, Brooks CJ, Burrows CL, Siebert S. Frequency 
and characteristics of disease flares in ankylosing spondylitis. Rheumatology 
2010;49(5):929–32.  
47.  Maksymowych W, Assoignon L. SAT0284 Disease activity in patients with ankylosing 
spondylitis considered candidates for anti-TNF therapy: How often and when should it 
be assessed? Ann Rheum Dis. 2014;71(Suppl 3):568–568.  
48.  Ubago R, Castillo M, Marin R, Flores S, Rodriguez R. Tumour necrosis factor alpha 
inhibitors for the treatment of active ankylosing spondylitis. Value Heal. 2011;A302.  
49.  Armstrong N, Joore M, Van Asselt T, Misso K, Manning N, Tomini F, et al. Golimumab 
for the treatment of ankylosing spondylitis: A nice single technology appraisal. 
Pharmacoeconomics. 2013;31(5):415–25.  
50.  Shu T, Chen G, Rong L, Feng F, Yang B, Chen R, et al. Indirect comparison of anti-
TNF-a agents for active ankylosing spondylitis: mixed treatment comparison of 
randomised controlled trials. Clin Exp Rheumatol. 2013;31:717–22.  
51.  Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in 
patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents 
infliximab and etanercept. Arthritis Rheum. 2005;52(8):2447–51.  
52.  Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the 
management of inflammatory bowel disease in adults. Gut. 2011;60(5):571–607.  
53.  Breban M. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-
month open-label study. Rheumatology 2002 Nov 1;41(11):1280–5.  
54.  Pedersen SJ, Sørensen IJ, Hermann K-GA, Madsen OR, Tvede N, Hansen MS, et al. 
Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and 
clinical and MRI measures of disease activity in a 1-year follow-up study of patients 
with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann 
Rheum Dis. 2010 Jun;69(6):1065–71.  
55.  Machado P, Landewe RBM, Braun J, Baraliakos X, Hermann K-G a., Hsu B, et al. 
MRI inflammation and its relation with measures of clinical disease activity and 
different treatment responses in patients with ankylosing spondylitis treated with a 
tumour necrosis factor inhibitor. Ann Rheum Dis. 2012;71(12):2002–5.  
BSR axSpA biologics full guideline 
 
28 
 
56.  Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J. Long-term efficacy of 
adalimumab after drug withdrawal and retreatment in patients with active non-
radiographically evident axial spondyloarthritis who experience a flare. Arthritis 
Rheum. 2013;65(8):2211–3.  
57.  Song I-H, Althoff CE, Haibel H, Hermann K-GA, Poddubnyy D, Listing J, et al. 
Frequency and duration of drug-free remission after 1 year of treatment with 
etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the 
ESTHER trial. Ann Rheum Dis. 2012;71(7):1212–5.  
58.  Fautrel B, Benhamou M, Breban M, Roy C, Lenoir C, Trape G, et al. Cost 
effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: 
economic evaluation within a randomised controlled trial. Ann Rheum Dis. 
2010;69(2):424–7.  
59.  Breban M, Ravaud P, Claudepierre P, Baron G, Henry Y-D, Hudry C, et al. 
Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year 
randomized controlled trial comparing systematic versus on-demand treatment. 
Arthritis Rheum. 2008;58(1):88–97.  
60.  Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-
Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the 
management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896–904.  
61.  Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, et al. Clinical trial safety 
and mortality analyses in patients receiving etanercept across approved indications. J 
Drugs Dermatol. 2011;10(3):289–300.  
62.  Villiger PM, Caliezi G, Cottin V, Förger F, Senn A, Østensen M. Effects of TNF 
antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum 
Dis. 2010;69(10):1842–4.  
63.  Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, et al. Impact of 
synthetic and biologic disease-modifying antirheumatic drugs on antibody responses 
to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, 
parallel-cohort, single-center study. Arthritis Rheum. 2011;63(6):1486–96.  
64.  Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, et al. Protective effect 
of A/H1N1 vaccination in immune-mediated disease-a prospectively controlled 
vaccination study. Rheumatology 2012;51(4):695–700.  
65.  Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. 
Antibody response is reduced following vaccination with 7-valent conjugate 
pneumococcal vaccine in adult methotrexate-treated patients with established 
arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 
2011;63(12):3723–32.  
66.  França ILA, Ribeiro ACM, Aikawa NE, Saad CGS, Moraes JCB, Goldstein-
Schainberg C, et al. TNF blockers show distinct patterns of immune response to the 
pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology 
2012;51(11):2091–8.  
BSR axSpA biologics full guideline 
 
29 
 
67.  Salisbury D, Ramsay M, editors. Immunisation against infectious disease. London: 
Public Health England; 2013.  
68.  Kim E-M, Uhm W-S, Bae S-C, Yoo D-H, Kim T-H. Incidence of tuberculosis among 
korean patients with ankylosing spondylitis who are taking tumor necrosis factor 
blockers. J Rheumatol. The Journal of Rheumatology; 2011;38(10):2218–23.  
69.  Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-
specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF 
therapy: results from the British Society for Rheumatology Biologics Register 
(BSRBR). Ann Rheum Dis. 2010;69(3):522–8.  
70.  Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, 
Martín-Mola E. Do TNF-blockers reduce or induce uveitis? Rheumatology 2008 
May;47(5):731–2.  
71.  Sieper J, Koenig a, Baumgartner S, Wishneski C, Foehl J, Vlahos B, et al. Analysis of 
uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum 
Dis. 2010;69(1):226–9.  
72.  Harbour R, Miller J. A new system for grading recommendations in evidence based 
guidelines. BMJ. 2001;323(7308):334–6.  
73.  Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans B a C, Braun J, et al. 
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a 
multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 
2006;54(7):2136–46.  
74.  Hu Z, Xu M, Li Q, Lin Z, Liao Z, Cao S, et al. Adalimumab significantly reduces 
inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in 
active ankylosing spondylitis. Int J Rheum Dis. 2012;15(4):358–65.  
75.  Huang F, Gu J, Zhu P, Bao C, Xu J, Xu H, et al. Efficacy and safety of adalimumab in 
Chinese adults with active ankylosing spondylitis: results of a randomised, controlled 
trial. Ann Rheum Dis. 2014;73:587–94.  
76.  Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of 
tumor necrosis factor alpha. N Engl J Med. 2002;346(18):1349–56.  
77.  Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, et al. Six-
month results of a double-blind, placebo-controlled trial of etanercept treatment in 
patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48(6):1667–75.  
78.  Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. 
Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating 
Ankylosing Spondylitis: A Randomized, Controlled Trial. Arthritis Rheum. 
2003;48(11):3230–6.  
79.  Calin A, Dijkmans B, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. 
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing 
spondylitis. Ann Rheum Dis. 2004;63(12):1594–600.  
BSR axSpA biologics full guideline 
 
30 
 
80.  Inman RD, Davis JC, Van Der Heijde D, Diekman L, Sieper J, Sung IK, et al. Efficacy 
and safety of golimumab in patients with ankylosing spondylitis: Results of a 
randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 
2008;58(11):3402–12.  
81.  Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, et al. Safety and efficacy of 
golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a 
multicentre, randomized, double-blind, placebo-controlled phase III trial. 
Rheumatology 2014;53(9):1654–63.  
82.  Braun J, Brandt J, Listing J, Zink a., Alten R, Golder W, et al. Treatment of active 
ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. 
Lancet. 2002;359(9313):1187–93.  
83.  Van Den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, et al. 
Randomized double-blind comparison of chimeric monoclonal antibody to tumor 
necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis 
Rheum. 2002;46(3):755–65.  
84.  Van Der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. 
Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a 
randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–91.  
 
 
 
 
  
BSR axSpA biologics full guideline 
 
31 
 
Table 1: System for assessing quality of studies and determining strength of 
recommendation 
Levels of evidence 
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a 
very low risk of bias. 
1+ Well conducted meta-analyses, systematic reviews, or RCTs with a low 
risk of bias. 
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias. 
2++ High quality systematic reviews of case control or cohort studies. 
 
High quality case control or cohort studies with a very low risk of 
confounding or bias and a high probability that the relationship is causal. 
2+ Well conducted case control or cohort studies with a low risk of 
confounding or bias and a moderate possibility that the relationship is 
causal. 
2- Case control or cohort studies with a high risk of confounding or bias and a 
significant risk that the relationship is not causal. 
3 Non-analytic studies e.g. case reports, case series. 
4 Expert opinion. 
 
Strength of recommendation 
A Directly based on level 1 evidence 
B Level 2 evidence, or extrapolation from level 1 
C Level 3 evidence, or extrapolation from levels 1 or 2 
D Level 4 evidence, or extrapolation from levels 2 or 3 
Adapted from Harbour and Miller BMJ 2001[72]. RCT: randomised controlled trial. 
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Medline 2086 
EMBASE 5823 
Cochrane 250 
8159 abstracts 
reviewed 
Efficacy: 
21 meta-analyses and 
systematic reviews 
103 RCTs 
5 cohort studies 
1 Delphi exercise 
 
 
Safety: 
7 systematic reviews 
2 RCTs 
18 cohort studies 
 
 
Rejected: 
Basic science - 93 
Editorial - 219 
Not biologics - 874 
Not human - 8 
Not outcome of 
interest - 739 
Not SpA - 2530 
Peripheral SpA - 29 
Review article 1311 
Case report - 530 
No abstract - 3 
Uncontrolled effiacy 
study - 667 
Previous guidelines - 49 
Paper not available - 6 
Conference abstract > 2 
years old - 405 
Uncontrolled safety 
study - 184 
 
355 duplicates 
Figure 1 – results of systematic 
literature review 
BSR axSpA biologics full guideline 
 
33 
 
 
 
Figure 2 – Treatment algorithm for biologic therapy in axSpA. 
BASDAI, Bath AS disease activity score; BMO, bone marrow oedema; CRP, C-reactive 
protein; NSAIDs, non-steroidal anti-inflammatory drugs; VAS, visual analogue score.
Meets modified New York criteria or has BMO in sacroiliac  
joints on MRI? 
No 
HLA-B27 
status +ve 
-ve 
Not 
suitable for 
biologics – 
disease 
inactive or 
unlikely to 
progress. 
CRP 
elevated? 
No 
Yes 
Yes 
BASDAI and spinal 
VAS ≥ 4 despite 
standard therapy? 
No 
Yes 
Consider trial of 
biologics 
Standard therapy is defined as two NSAIDs for 
at least two weeks each unless 
contraindicated. 
In the event that a patient is unable to 
complete a BASDAI, the decision to initiate 
and continue treatment should be based on 
the treating physician’s assessment . 
Assess efficacy after 3-
6 months. Consider 
switching to another  
biologic drug in event 
of side effects or 
inefficacy. 
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Table 2 – summary of efficacy studies of biologics drugs in AS and nr-axSpA found to be of high or acceptable quality.  
RCTs of anti-TNF drugs in AS 
 
 
 
 
 
Inclusion criteria for 
study 
 
 
  
  
  
  
  
Author 
[ref] Intervention Dose Comparator 
N
um
ber: 
A
ctive arm
 
N
um
ber: 
C
om
parator 
arm
  Pts 
meet 
mNY 
criteria 
B
A
S
D
A
I ≥ 4 
NSAID fail 
inclusion 
criteria 
Duration 
(weeks) 
Primary 
Outcome 
Primary result 
(active vs 
comparator) Other outcomes 
 
van der 
Heijde et 
al [73]  Adalimumab 
40mg 
Q2W PBO 208 107 Y Y Y 12 ASAS20 58.2% vs 20.6% 
ASAS20 wk 24 (66% v 0%); BASDAI50 wk 12 (45.2 v 
15.9%) ASAS40 wk12 (39.1 v 13.1%) 
Hu et al  
[74] Adalimumab 
40mg 
Q2W PBO 26 20 Y Y Y 12 
None 
specified __ BASDAI, BASFI, ASDAS, MRI and biomarkers 
Huang et 
al  
[75] Adalimumab 
40mg 
Q2W PBO 229 115 
Y 
(Chinese 
only) Y Y 12 ASAS20 67.2% vs 30.4% 
ASAS40 (44.5% vs 9.6%); ASAS5/6 (55.9% vs 12.2%); 
ASAS PR (21.8% vs 3.5%); BASDAI50 (49.8% vs 
16.5%) 
Landewe 
et al [34] Certolizumab 
200mg 
Q2W or 
400mg 
Q4W PBO 218 107 
AS (178) 
& 
nrAxSpA 
(147) Y Y 12 ASAS20 
57.7%(Q2W); 
63.6%(Q4W) vs 
38.3% 
Results similar in AS and axSpA groups; ASAS40 
(43.2%; 48.6% vs 17.8%); ASAS PR (23.4%; 24.3% vs 
3.7%); BASDAI, PROs 
Gorman 
et al  
[76] Etanercept 
25mg 
BIW PBO 20 20 Y _ _ 16 ASAS20 80% vs 20% - 
Brandt et 
al  
[77] Etanercept 
25mg 
BIW PBO 14 16 Y Y _ 6 BASDAI50 57% vs 6% - 
Davis et 
al  
[78]  Etanercept 
25mg 
BIW PBO 138 139 Y _ _ 24 ASAS20 57% vs 22% 
ASAS20 at 12wk (59% vs 28%); ASAS50 & 70; BASDAI; 
acute phase response 
Calin et 
al [79] Etanercept 
25mg 
BIW PBO 45 39 Y _ _ 12 ASAS20 60.0% vs 23.1% ASAS40 (49% v 10%); ASAS70 (24% vs 10%); BASDAI 
van der 
Heijde et 
al [20] Etanercept 
50mg 
QW or 
25mg 
BIW PBO 305 51 Y _ _ 12 ASAS20 
74%(QW); 
71%(BIW) vs 
37% 
ASAS40 (58.1%; 53.3% vs 21.6%); ASAS 5/6 (70.3%; 
72.0% vs 27.5%), 
Braun et 
al [18] Etanercept 
50mg 
QW SSZ 379 187 Y >3 _ 16 ASAS20 75.9% vs 52.9% 
ASAS20 at 12wk (70.9% vs 52.4%); ASAS40; ASAS5/6; 
mean BASDAI; BASMI; BASFI; physician and pt global 
Dougado
s et 
al[25]  Etanercept 
50mg 
QW PBO 39 43 
Y + 
advance
disease Y Y 12 
AUC 
BASDAI (-19.8 vs -11.0) 
ASAS20 (67% vs 33%); ASAS40 (44% vs 23%); 
BASDAI50 (46% vs 23%) 
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Navarro-
Sarabia 
et al [19] Etanercept 
50mg 
BIW 
Etanercept 
50mg QW 54 54 Y Y Y 12 ASAS20 
63%(BIW) vs 
68.5%(QW)  ASAS40 (both 46%)  
Inman et 
al[80] 
Golimumab 
50mg 
Q4W or 
100mg 
Q4W PBO 278 78 Y Y Y 14 ASAS20 
59.6%(50mg); 
60% (100mg) vs 
21.8% 
ASAS40 at 24wk (44%; 54% vs 15%); ASAS20 at 24 wk 
(similar to 14wk); mean BASDAI, BASFI; others plus 
PROs 
Bao et al 
[81] 
Golimumab 
50mg 
Q4W PBO 108 105 
Y 
(Chinese 
only) Y _ 14 ASAS20 24.8% vs 49.1% 
ASAS20 at wk 24 (22.9% vs 50.9%); ASAS40; BASDAI; 
BASFI; others inc. PROs 
Braun et 
al[82] Infliximab 5mg/kg PBO 34 35 Y Y _ 12 BASDAI50 53% vs 9%  ASAS20; ASAS50; ASAS PR; fatigue from BASDAI 
Van Den 
Bosch et 
al [83] Infliximab 5mg/kg PBO 20 20 
ESSG 
SpA 
(21=AS) _ _ 12 
Phys global 
& Pt global _ BASDAI change for the 21 AS patients = -3.23 vs -0.26 
Marzo-
Ortega 
et al [22] 
Infliximab + 
MTX 5mg/kg PBO + MTX 28 14 
Y 
(+CRP>
10) _ Y 30 BASDAI 
N/S (8wk after 
last infusion)  
van der 
Heijde et 
al [84] 
 
Infliximab 
 
 
5mg/kg 
 
 
PBO 
 
 
201 
 
 
78 Y Y Y 24 ASAS20 61.2% vs 19.2% ASAS40 (47% v 12%); BASDAI50 (51% vs 11%); ASAS5/6; ASASPR 
Pathan 
et al[32]  Apremilast 
30mg 
bd PBO 17 19 Y ? _ 12 
Change in 
BASDAI 
 N/S (-1.59 vs -
0.77) 
ASAS20 (35.3% vs 15.8%); BASMI; BASFI; bone 
biomarkers 
Park et 
al [26] 
 
CT-P13 
(biosimilar 
infliximab) 5mg/kg Infliximab 125 125 Y Y ? N/A 
PK 
equivalence _ 
ASAS20 at 14 wk (62.6% vs 70.5%); ASAS40 at 14 wk 
(41.7% vs 51.8%); ASAS20 and ASAS40 at 30 wk (no 
stat sign diff in clinical response at wk 14 or 30); BASDAI 
change; SF36 
Baeten 
et al[30] Secukinumab 
2 x 
10mg/k
g PBO 24 6 Y Y Y 
6 
(Bayesian) ASAS20 59% vs 24%  (99.8% probability secukinumab superior to PBO) 
Haibel et 
al[37] Adalimumab 
40mg 
Q2W PBO 22 24 All -ve N N 12 ASAS40 54.5% vs 12.5%  
 
BASDAI at 12 weeks ADA 3.8, PBO 5.0 (p=0.036) 
Barkham 
et al[35] Inflximab 5mg/kg  PBO 20 20 12% Y N 12 
MRI score 
SIJ and 
spine 
Median change -
2 IFX vs O PBO 
(p=0.033) 
BASDAI -3.41 IFX vs 0.75 PBO (p=0.033) 
BASFAI -2.7 IFX vs 0.47 PBO (p=0.004) 
Sieper et 
al[36]  
Infliximab + 
naproxen  
PBO + 
naproxen 105 51 
57.5% 
+ve  Y 
N (could 
be naïve) 28 
ASAS 
partial 
remission 
61.9% vs 35.3% 
(p=0.002)  
Song et 
al [33] Etanercept  
25mg 
Q2W SSZ or MTX 40 36 
51.3% 
+ve Y Y 48 
MRI SIJ 
score 
ETN 2.4, SSZ 
3.5 (p=0.02) 
BASDAI ETN 2.5 
SSZ 4.4 
P=0.001 
 
BASFI ETN 2.0 
SSZ 3.3 
P=0.001 
Sieper et 
al[38] Adalimumab 
40mg 
q2w PBO 91 94 All -ve Y Y 12 ASAS40 
36% vs 15% 
(p<0.001) 
BASDAI -1.9 ADA vs -1.0 PBO (p=0.004) 
BASFI -1.1 ADA vs -0.6 PBO (p=0.053)  
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Landewe 
et al [34] Certolizumab 
200mg 
Q2W or 
200mg 
Q4W PBO 
111 and 
107 107 
54.8% 
+ve  Y Y 24 
ASAS20 wk 
12 
57.7% Q2W and 
63.6% Q4W vs 
38.3% (p<0.004) 
No difference in treatment effect between AS and nr-
axSpA 
mNY: modified New York; QW: every week; Q2W: every 2 weeks; Q4W: every 4 weeks; BIW: twice weekly;  PBO: placebo; SSZ: sulfasalazine; 
MTX: methotrexate; Y:Yes ; N:No ; ASAS20: ASAS 20% response criteria; ASAS 40: ASAS 40% response criteria ; ASAS PR: ASAS partial 
remission criteria ; ETN: etanercept ; N/S: not significant ; SIJ: sacroiliac joint; IFX: infliximab ; PT: patient ;PK: pharmacokinetic; SF36: 36-item 
Short Form Health Survey; 
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Appendix 
 
Structured questions 
• What is the efficacy of biologics in axial SpA (radiographic and non-radiographic)? 
• Is there evidence for a difference in efficacy and safety between different drugs? 
• What is the evidence for switching biologics? 
• Is there evidence on withdrawing biologics? 
• Evidence for intermittent use of biologics? 
• Evidence for changing dose? 
• What are the best predictors of response to treatment? 
• Is there a difference in efficacy when patients are treated early vs late in disease 
course? 
• What are the eligibility criteria for biologics? 
• What outcome measures should be used? 
• How do we define remission? 
• Do biologics affect radiographic outcome? 
• Do biologics affect extra-articular features of SpA? 
• Do biologics have an effect on work productivity/absenteeism? 
• Do biologics affect utilisation of health care? 
• Are biologics associated with an increased risk of: infection (bacterial, fungal, viral), 
malignancy, immunogenicity, neurological disease or other side effects? 
• Are biologics safe around the time of conception (male and female), during 
pregnancy and during lactation? 
• Are biologics safe to use in patients with viral hepatitis or HIV? 
 
